Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Cancer immunotherapy using dendritic cells, and iii) Camel recombinant antibodies for FoxP3, Mucl & CEA. More
Heart failure is associated with cardiac hypertropy, atheiosclerosis, myocardial infarction, valvular heart disease and hypertension. Many researches has focused on development of cardiotonics for treating heart failure. More
Related Reports
Market Research Reports provided by reports.iptechex.com
May 2011 - 15 pages - $250
May 2008 - 70 pages - $1,999
May 2011 - 15 pages - $125
Oct 2010 - 25 pages - $250
May 2011 - 25 pages - $125
Nov 2010 - 28 pages - $600
Oct 2009 - 30 pages - $995
May 2011 - 25 pages - $125
Sep 2010 - 25 pages - $125
Apr 2011 - 26 pages - $125
Your selection
Browse By
- Therapeutic target
- Blood composition
- Blood disorders
- Blood substitute
- Blood Transfusion
- Fibrogenesis
- Hemorrhagic trauma
- Lymphatic disorders
- Sepsis
- Thrombosis
- Whole blood substitute
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us